Based on all of the above results, we suggest that T56-LIMKi has promising therapeutic potential for acting as a safe inhibitor of cancer cells characterized by LIMK2 over-activation or by over-activation of LIMK2 upstream signaling pathways such as RhoA [20], P53 [33], and Aurora-A kinase pathways [34]. The gene discussed is LIMK2; the disease is cancer.